AR043253A1 - 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas - Google Patents

4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas

Info

Publication number
AR043253A1
AR043253A1 ARP040100546A ARP040100546A AR043253A1 AR 043253 A1 AR043253 A1 AR 043253A1 AR P040100546 A ARP040100546 A AR P040100546A AR P040100546 A ARP040100546 A AR P040100546A AR 043253 A1 AR043253 A1 AR 043253A1
Authority
AR
Argentina
Prior art keywords
injuries
metoxifenil
dicloro
alcoxi
ischemical
Prior art date
Application number
ARP040100546A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR043253A1 publication Critical patent/AR043253A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos que tienen la fórmula (1), en la cual: X es N, CH; n es un número entero de 1-3; y R' y R son independientemente, alquilo C1-3, y las sales de dichos compuestos farmacéuticamente aceptables, con la condición de que cuando n es 1, X no es N; que son útiles para inhibir la permeabilidad vascular causada por enfermedades, lesiones u otros traumas. Composición farmacéuticas que los comprenden.
ARP040100546A 2003-02-21 2004-02-20 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas AR043253A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
AR043253A1 true AR043253A1 (es) 2005-07-20

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100546A AR043253A1 (es) 2003-02-21 2004-02-20 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas

Country Status (19)

Country Link
US (1) US20040229880A1 (es)
EP (1) EP1594502A1 (es)
JP (1) JP2006522023A (es)
KR (1) KR20050102133A (es)
CN (1) CN1750824A (es)
AR (1) AR043253A1 (es)
AU (1) AU2004216235A1 (es)
BR (1) BRPI0407441A (es)
CA (1) CA2516418A1 (es)
CO (1) CO5640114A2 (es)
CR (1) CR7931A (es)
EC (1) ECSP055972A (es)
MX (1) MXPA05008706A (es)
NO (1) NO20054070L (es)
RU (1) RU2005129333A (es)
TW (1) TW200423938A (es)
UA (1) UA80472C2 (es)
WO (1) WO2004075898A1 (es)
ZA (1) ZA200506621B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
RU2007111704A (ru) * 2004-10-22 2008-11-27 Вайет (Us) 4[(2,4-дихлоро-5-метоксифенил)амино]-6-алкокси-7-этинил-3-хинолинкарбонитрилы для лечения ишемического поражения
ES2449197T5 (es) * 2005-07-01 2022-04-28 Wyeth Llc Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3- quinolincarbonitrilo y procedimientos de preparación de las mismas
RU2582610C2 (ru) 2010-07-30 2016-04-27 Онкотерапи Сайенс, Инк. Производные хинолина и содержащие их ингибиторы melk
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
CN108697661A (zh) 2015-12-18 2018-10-23 亚尼塔公司 用于治疗癌症的组合
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
JP7203083B2 (ja) 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CA2500368A1 (en) * 2002-10-04 2004-04-22 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
JP2006522023A (ja) 2006-09-28
WO2004075898A1 (en) 2004-09-10
BRPI0407441A (pt) 2006-01-31
AU2004216235A1 (en) 2004-09-10
TW200423938A (en) 2004-11-16
ZA200506621B (en) 2008-02-27
CN1750824A (zh) 2006-03-22
MXPA05008706A (es) 2005-10-05
KR20050102133A (ko) 2005-10-25
CA2516418A1 (en) 2004-09-10
CO5640114A2 (es) 2006-05-31
US20040229880A1 (en) 2004-11-18
NO20054070L (no) 2005-11-14
ECSP055972A (es) 2006-01-16
RU2005129333A (ru) 2006-01-27
UA80472C2 (en) 2007-09-25
CR7931A (es) 2006-02-07
NO20054070D0 (no) 2005-09-01
EP1594502A1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
CY1111693T1 (el) Αντιιικοι παραγοντες
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
PA8547701A1 (es) Nucleosidos 4 substituidos.
UY28376A1 (es) Agentes terapéuticos
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
CY1111471T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal